Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child

Bromley, Rebecca; Pulman, Jennifer; Greenhalgh, J; Dickson, Rumona; McKay, A. J.; Smith, Catrin Tudur; Marson, Anthony G

doi:10.1002/14651858.cd010236

Cited by 62 publications

(140 citation statements)

References 24 publications

Supporting

Mentioning

128

Contrasting

Unclassified

Order By: Relevance

“…The estimated difference to children of untreated women with epilepsy is approximately 8 IQ points (Bromley et al, 2014; National Institute for Health and Care Excellence, 2015a). In women with epilepsy, the risk of ASD is reported to be doubled from around 2% to 4% with in utero exposure to valproate, and childhood autism 3 fold from 1% to 3% .…”

Section: Neurodevelopmental Effectsmentioning

confidence: 99%

See 1 more Smart Citation

British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017

et al. 2017

View full text Add to dashboard Cite

Decisions about the use of psychotropic medication in pregnancy are an ongoing challenge for clinicians and women with mental health problems, due to the uncertainties around risks of the illness itself to mother and fetus/infant, effectiveness of medications in pregnancy and risks to the fetus/infant from in utero exposure or via breast milk. These consensus guidelines aim to provide pragmatic advice regarding these issues. They are divided into sections on risks of untreated illness in pregnancy; general principles of using drugs in the perinatal period; benefits and harms associated with individual drugs; and recommendations for the management of specific disorders.

show abstract

Section: Neurodevelopmental Effectsmentioning

confidence: 99%

“…Current evidence does not suggest that carbamazepine is associated with poorer cognitive development (Bromley et al, 2014) or ASD (Bromley et al, 2014;Christensen et al, 2013; National Institute for Health and Care Excellence, 2015a).…”

Section: Neurodevelopmental Effectsmentioning

confidence: 99%

British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Use of AEDs in monotherapy and to avoid having teratogenic AED effects is recommended during pregnancy. Mothers with epilepsy are free to continue with the breast feeding their newborns [13][14][15].…”

Section: Resultsmentioning

confidence: 99%

Congenital Malformations in Newborns of Mothers Affected by Epilepsy

Jovandaric¹

2015

Clinics Mother Child Health

View full text Add to dashboard Cite

Aim: To examine the effects of anti-epileptic drugs (AED) used during pregnancy on the frequency and the type of congenital malformations in newborns. Methods:The study included 96 newborns, born by mothers affected by epilepsy (before the pregnancy). The control group consisted of 96 healthy newborns delivered by mothers.Results: Almost all of the pregnant women used AED (98%) during the pregnancy. Monotherapy (Phenobarbiton) was used in 80% of women and 18% was used polytherapy, respectively. The pregnancy ended vaginal delivery in 54.4% of women, and in 45.5% of women, it is ended by cesarean section. Congenital malformations (palatoshisis and ventricular septal defect-VSD) were observed after births in 3 of newborn by means of detailed clinical and ehosonographic survey. Both pregnant women were on polytherapy (Phenobarbiton and Karbamazepin). Congenital malformations were not observed in the control group of newborns delivered by healthy mothers. Conclusion:The use of AED in the form of monotherapy and avoiding of AED that have the teratogenic effect are recommended during the pregnancy. Mothers with epilepsy are free to continue with the breast feeding their newborns.

show abstract

“…It must also be used with extreme caution in women of child-bearing age as increasing evidence links the use of valproate in pregnancy with adverse neurodevelopmental outcomes in the child. 45 There are a few other oral migraine preventive therapies with some supportive evidence from clinical trials. Candesartan 16 mg was shown in a small double-blind placebo-controlled crossover trial over 12 weeks to reduce the mean number of headache days from 18.5 with placebo to 13.6 with candesartan, with a 50% responder rate of 40.4%.…”

Section: Preventive Treatment Of Migrainementioning

confidence: 99%

Drug therapy in headache

Weatherall

2015

Clinical Medicine

View full text Add to dashboard Cite

All physicians will encounter patients with headaches. Primary headache disorders are common, and often disabling. This paper reviews the principles of drug therapy in headache in adults, focusing on the three commonest disorders presenting in both primary and secondary care: tension-type headache, migraine and cluster headache. The clinical evidence on the basis of which choices can be made between the currently available drug therapies for acute and preventive treatment of these disorders is presented, and information given on the options available for the emergency parenteral treatment of refractory migraine attacks and cluster headache.

show abstract

Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child

Cited by 62 publications

References 24 publications

British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017

British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017

Congenital Malformations in Newborns of Mothers Affected by Epilepsy

Drug therapy in headache

Contact Info

Product

Resources

About